• News
  • SAN DIEGO
  • BioTech

La Jolla Pharmaceutical expands team

La Jolla Pharmaceutical Company made two additions to its management team.

The biopharmaceutical company develops medical treatments for life-threatening diseases.

Stacey Ruiz, Ph.D., was hired as director of research and development, and Chester S. Zygmont III was named director of finance.

Ruiz will be working on the development of La Jolla Pharma's pipeline drug candidates alongside James Rolke, senior director of research and development and patentee for the technology behind GCS-100.

GCS-100, the company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer.

Zygmont will be leading the management of all financial responsibilities including accounting, regulatory reporting, investor relations, and treasury.

Ruiz comes to La Jolla Pharma after five years at Reata Pharmaceuticals, most recently working on bardoxolone methyl for the treatment of chronic kidney disease.

Zygmont joins La Jolla Pharma following his role at investment firm Z3 Capital LLC where he served as managing director. Zygmont also served as vice president at Symmetry Advisors, a private equity leverage buyout firm in New York City.

"We are now positioned to effectively advance the development of our pipeline with the goal of commercializing products that can help those suffering and in need of better treatments," said George Tidmarsh, M.D., Ph.D., president and CEO of La Jolla Pharma.

RELATED ARTICLE:

La Jolla Pharmaceutical gets investment

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

La Jolla Pharmaceutical Co.

Company Website

6455 Nancy Ridge Dr.
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
LJPC
23.87
  -0.82  
- 3.32%
149,217,000
44.99
7.97

Insider Trade Data

Date Insider Shares Type Value
09/28/2015 Chawla, Lakhmir S 485 Purchase $13,461
09/28/2015 Chawla, Lakhmir S 485 Purchase $13,461
09/10/2015 Tang, Kevin C 80,000 Purchase $3,040,000
09/10/2015 Tang, Kevin C 80,000 Purchase $3,040,000
08/21/2015 Tang, Kevin C 170,000 Purchase $4,609,230

La Jolla Pharmaceutical Co. Executive(s):

Deirdre Gillespie

  • Chief Executive Officer, President

George Tidmarsh

  • Chief Executive Officer, President

Similar Companies

NAICS - 541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)